SANERON CCEL THERAPEUTICS, INC.

Basic Information

3802 Spectrum Blvd.
TAMPA, FL, 33612-

Company Profile

n/a

Additional Details

Field Value
DUNS: 39606491
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    Amount: $422,946.00

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier ...

    STTR Phase I 2013 Department of Health and Human Services
  2. Neuroprotective therapy of stroke with HUCNC and simvastatin

    Amount: $176,926.00

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells ( ...

    STTR Phase I 2010 Department of Health and Human Services
  3. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    Amount: $2,608,660.00

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative dise ...

    STTR Phase II 2010 Department of Health and Human Services
  4. Transplantation of Umbilical Cord Blood Stem Cells in Ischemic Brain Injury

    Amount: $96,315.00

    DESCRIPTION (provided by applicant): Human umbilical cord blood is a rich source of hematopoietic stem cells that can be used to re-populate the blood and immune systems. In preliminary studies we hav ...

    STTR Phase I 2008 Department of Health and Human Services
  5. HUCBC modulation of Alzheimer-like pathology and behavioral changes

    Amount: $140,383.00

    DESCRIPTION (provided by applicant): Modulation of the inflammatory cascade by several diverse strategies including A immunization, non-steroidal anti-inflammatory drug (NSAID) administration, and man ...

    STTR Phase I 2007 Department of Health and Human Services
  6. Cord Blood: Treatment for Acute Myocardial Infarction

    Amount: $184,249.00

    DESCRIPTION (provided by applicant): Transplantation of human umbilical cord stem cells (hUCBC) has been shown to be effective in limiting infarct size and in the preservation of left ventricular func ...

    STTR Phase I 2005 Department of Health and Human Services
  7. Hemorrhagic Brain Injury Repair with Human Cord Blood

    Amount: $158,697.00

    DESCRIPTION (provided by applicant): Human umbilical cord blood (hUCB) is a rich source of stem cells that exhibit multipotent properties. Previous studies have shown that hUCB cells can differentiate ...

    STTR Phase I 2005 Department of Health and Human Services
  8. Sertoli Treated Cord Blood for Spinal Cord Injury

    Amount: $150,000.00

    DESCRIPTION (provided by applicant): Stem cells from human umbilical cord blood (hUCB) represent a promising cellular therapeutic strategy for the treatment of cord injury (SCI). These cells are capab ...

    SBIR Phase I 2004 Department of Health and Human Services
  9. Cord Blood Cells in ALS: Replacement of Protection?

    Amount: $144,366.00

    DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease affecting motor neurons in the spinal cord, brainstem and cortex. We have previously shown that ...

    STTR Phase I 2004 Department of Health and Human Services
  10. Sertoli Cell-Treated Umbilical Cord Blood for Stroke

    Amount: $133,060.00

    DESCRIPTION (provided by applicant): With the recent observations that stem-like cells outside the central nervous system (CNS) can differentiate into neurons, it is no longer inconceivable to sugges ...

    STTR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government